Kung Winston 4

What Happened

• Winston Kung, Chief Financial Officer of ArriVent BioPharma (AVBP), received a derivative equity award covering 140,000 shares on 2026-02-02. The filing reports an acquisition price of $0.00 and a reported value of $0. This is an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Award amount: 140,000 shares (derivative award reported at $0.00).
• Shares owned after transaction: not specified in the Form 4.
• Footnote (vesting): 25% of the shares underlying this option vest on February 2, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• Transaction type: derivative award/option grant (no immediate cash exchanged or sale).

Context

• This award appears to be a time-based equity grant intended to align the CFO’s interests with shareholders; vesting schedule means the shares are not immediately vested or transferable. Derivative awards do not represent immediately realized proceeds unless exercised and/or sold later. Such grants are routine for executive compensation and do not by themselves indicate a buy or sell sentiment.